Opus Genetics Q3 Financials & Cash Runway into 2029
Opus Genetics reported Q3 2026 financials with significant public and private milestone payments providing cash runway into 2029. The company advanced gene therapy programs with OPGx-LCA5 enrolling a Phase 3 trial and OPGx-BEST1 Cohort 2 dosing complete.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed